Clinical trials: Acute Cardiovascular Disease
Paroxysmal Atrial Fibrillation (PAF)
INhalation of Flecainide to Convert Recent Onset SympTomatic Atrial Fibrillation to siNus rhyThm (INSTANT)
The study consisted of 3 parts (Part A, Part B and Part C). Part A was an open-label, randomized, multi center design to evaluate the feasibility of administration of inhaled flecainide in two dosing regimens.
- Trial name
- INSTANT (NCT03539302)
- Testing
- Flecainide Acetate
- Where
- 9 sites in Belgium, Netherlands
- Volunteers
- 176 people
- Sponsor
- InCarda Therapeutics, Inc.
Acute Decompensated Heart Failure
Gas Exchange for Predicting Hospital Heart Failure Readmissions
To determine whether, and if so, which gas exchange parameters measured on the Shape-HF Cardiopulmonary Exercise Testing System predict 30 and 180 day re-hospitalization in subjects discharged from hospitalization for an episode…
- Trial name
- NCT01960218
- Where
- 7 sites in United States
- Volunteers
- 120 people
- Sponsor
- Shape Medical Systems, Inc.
Acute Myeloid Leukemia, Acute Lymphoid Leukemia
HA-1H TCR T Cell for Relapsed/Persistent Hematologic Malignancies After Allogeneic Stem Cell Transplantation
This is a non-randomised, open-label phase I study of an investigational medicinal product (IMP) consisting of a HLA-A*02:01 restricted HA-1H T cell receptor transduced T cell (MDG1021) immunotherapy for relapsed or persistent…
- Conditions
- Acute Myeloid Leukemia, Acute Lymphoid Leukemia, Myelodysplastic Syndromes, Myeloproliferative Disorders
- Trial name
- NCT04464889
- Testing
- MDG1021 dose 1, MDG1021 dose 2, MDG1021 dose 3
- Where
- Netherlands
- Sponsor
- Medigene AG
Hypertension, Hypoxia
The VISION-Acute Study
AIM: We propose an innovative approach using Lifelight® smart technology that will enable the continued provision of high level patient care at the same time as reducing pressure on nursing and equipment resources.
- Conditions
- Hypertension, Hypoxia, Hypotension
- Trial name
- NCT04589923
- Testing
- Lifelight® Data Collect Blood Pressure Group, Lifelight® Data Collect Oxygen Saturation Group
- Where
- United Kingdom
- Volunteers
- 127 people
- Sponsor
- Xim Limited
Acute Ischemic Stroke
BXOS110 Injection in the Treatment of Acute Ischaemic Stroke
The purpose of this study was to evaluate the effectiveness of early administration of BXOS110 for injection in reducing overall disability in patients with acute ischaemic stroke.
- Trial name
- NCT06322394
- Testing
- high-dose BXOS110, low-dose BXOS110
- Where
- 24 sites in China
- Volunteers
- 300 people
- Sponsor
- Biocells (Beijing) Biotech Co.,Ltd
ACS - Acute Coronary Syndrome, NSTEMI - Non-ST Segment Elevation MI
MCG Discovery Study in Emergency Departments
This prospective discovery study is designed to demonstrate the feasibility of using an unshielded, mobile MCG device in an Emergency Department (ED) setting.
- Trial name
- NCT06095557
- Testing
- Sponsor MCG device
- Where
- United States
- Volunteers
- 124 people
- Sponsor
- SB Technology, Inc.
Hyponatremia
THE BALANCE Study: Treatment of Hyponatremia Based on Lixivaptan in NYHA Class III/IV Cardiac Patient Evaluation
The purpose of this study is to determine the safety and efficacy of lixivaptan in the treatment of hyponatremia in patients with congestive heart failure.
- Trial name
- NCT00578695
- Testing
- lixivaptan
- Where
- 287 sites in United States, Argentina and 13 more
- Volunteers
- 652 people
- Sponsor
- CardioKine Inc.
Heart Failure, Cardiac Failure
Study of Heart Failure Hospitalizations After Aquapheresis Therapy Compared to Intravenous (IV) Diuretic Treatment
The purpose of the research is to determine if patients have fewer Heart Failure (HF) events after receiving Aquapheresis (AQ) therapy compared to intravenous (IV) diuretics up to 90 days of discharge from the hospital.
- Conditions
- Heart Failure, Cardiac Failure, Acute Decompensated Heart Failure (ADHF)
- Trial name
- AVOID-HF (NCT01474200)
- Testing
- Isolated veno-venous ultrafiltration (AQ), IV Loop Diuretics (LD)
- Where
- 38 sites in United States
- Volunteers
- 224 people
- Sponsor
- Nuwellis, Inc.
Acute Coronary Syndrome
A Comparison of Prasugrel and Clopidogrel in Acute Coronary Syndrome Subjects
This study will evaluate the relative efficacy and safety of prasugrel and clopidogrel in a medically managed Unstable Angina/Non-ST-Elevation Myocardial Infarction (UA/NSTEMI) acute coronary syndrome (ACS) population (that is…
- Trial name
- TRILOGY ACS (NCT00699998)
- Testing
- Clopidogrel, Prasugrel, Commercially-available Aspirin
- Where
- 688 sites in United States, Argentina and 51 more
- Volunteers
- 9,326 people
- Sponsor
- Eli Lilly and Company
Venous Thrombosis, Deep Vein Thrombosis
Oral Direct Factor Xa Inhibitor BAY59-7939 in Patients With Acute Symptomatic Proximal Deep Vein Thrombosis(ODIXa-DVT)
The purpose of this study is to compare the safety and efficacy of BAY59-7939 with the safety and efficacy of the licensed drug enoxaparin and a licensed oral vitamin K-antagonist and to find the optimal dose of BAY59-7939 for…
- Trial name
- NCT00839163
- Testing
- Xarelto (Rivaroxaban, BAY59-7939), Enoxaparin/Vitamin K-Antagonist
- Where
- 110 sites in Australia, Austria and 17 more
- Volunteers
- 613 people
- Sponsor
- Bayer
Pulmonary Embolism, Thrombotic Disease
Study to Assess the Safety, Pharmacokinetics/Dynamics of DS-1040b in Subjects With Acute Submassive Pulmonary Embolism
This is a Phase 1b, double-blind (participants and Investigators), placebo-controlled, randomized, single-ascending dose, multi-center study to assess the safety, efficacy, tolerability, pharmacokinetics (PK), and…
- Trial name
- NCT02923115
- Testing
- DS-1040b, Enoxaparin
- Where
- 46 sites in United States, Austria and 6 more
- Volunteers
- 134 people
- Sponsor
- Daiichi Sankyo
Hereditary Angioedema (HAE)
A Study of Icatibant for Acute Attacks of Hereditary Angioedema in Japanese Participants
The objective of this study is to evaluate the efficacy, pharmacokinetics (PK), and safety of icatibant for the treatment of acute attacks in Japanese participants with type I or type II hereditary angioedema (HAE).
- Trial name
- NCT03888755
- Testing
- Icatibant
- Where
- 8 sites in Japan
- Volunteers
- 8 people
- Sponsor
- Shire
Aortic Dissection
False Lumen Treatment for Prevention of Aortic Growth Using Shape Memory Polymer - First-in-Human Study (FLAGSHIP_CHL)
To determine the safety and feasibility of the investigational product to reduce aortic dissection false lumen perfusion.
- Trial name
- FLAGSHIP_CHL (NCT07387250)
- Testing
- False Lumen Embolization System, IMPEDE-FX RapidFill
- Volunteers
- 15 people
- Sponsor
- Shape Memory Medical, Inc.
Acute Ischemic Stroke
Safety and Efficacy Evaluation of the iNstroke 4F Thromboaspiration Catheter in Patients With Acute Ischaemic Stroke Due to Primary Distal Medium Vessel Occlusions (DMVO)
Prospective, Single-arm, Multi-centre Study to Evaluate the Efficacy and Safety of the iNstroke 4F Thromboaspiration Catheter in Patients with Acute Ischaemic Stroke due to Primary Distal Medium Vessel Occlusions.
- Trial name
- 4-NiVO (NCT07357285)
- Testing
- Thromboaspiration catheter
- Where
- 11 sites in Germany, Hungary and 1 more
- Volunteers
- 57 people
- Sponsor
- iVascular S.L.U.
Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
The purpose of this extension study is to provide venetoclax and obtain long-term safety data for subjects who continue to tolerate and derive benefit from receiving venetoclax in ongoing studies.
- Conditions
- Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia, Multiple Myeloma, Non-Hodgkin's Lymphoma
- Trial name
- NCT03844048
- Testing
- Venetoclax
- Where
- 56 sites in United States, Australia and 21 more
- Volunteers
- 165 people
- Sponsor
- AbbVie
Acute Coronary Syndrome
Outcomes in UK ACS Patients Prescribed Ticagrelor
Cohort study using data from Clinical Practice Research Datalink (CPRD). The study cohort includes all patients who received at least one prescription for ticagrelor for the first time between December 2010 and March 2015…
- Trial name
- NCT03058601
- Where
- United Kingdom
- Volunteers
- 1,650 people
- Sponsor
- AstraZeneca
Myocardial Infarction
A Trial Evaluating the Efficacy and Safety of Tenecteplase Together With Unfractionated Heparin Prior to Early Percutaneous Coronary Intervention (PCI) as Compared to Standard Primary PCI in Patients With Acute Myocardial Infarction (ASSENT 4 PCI)
To show whether addition of thrombolytic treatment by a single bolus injection of tenecteplase prior to early standard PCI (percutaneous coronary intervention) will improve the clinical outcome in patients with large acute…
- Trial name
- NCT00168792
- Testing
- Tenecteplase, PCI
- Where
- 176 sites in United States, Austria and 16 more
- Volunteers
- 1,671 people
- Sponsor
- Boehringer Ingelheim
Acute and Chronic Wounds, Pressure Ulcers
Clinical Evaluation of the SNaP Wound Care System
The purpose of this study is to assess the efficacy of design improvements of the Spiracur SNaP Wound Care System. This study prospectively evaluates the safety and efficacy of current and new design iterations of components of…
- Conditions
- Acute and Chronic Wounds, Pressure Ulcers, Trauma Wounds, Diabetic Foot Ulcers
- Trial name
- NCT01113658
- Testing
- SNaP Wound Care System
- Where
- 2 sites in United States
- Sponsor
- 3M
ST Elevation Myocardial Infarction
A Study to Evaluate the Safety and Efficacy of MEDI6012 in Acute ST Elevation Myocardial Infarction
This is a Phase 2b randomized, blinded, placebo controlled study to evaluate the efficacy, safety, PK/pharmacodynamic, and immunogenicity of repeat doses of MEDI6012 in adult participants presenting with acute STEMI (ST segment…
- Trial name
- REAL-TIMI 63B (NCT03578809)
- Testing
- MEDI6012
- Where
- 37 sites in Brazil, Czechia and 8 more
- Volunteers
- 593 people
- Sponsor
- MedImmune LLC
Myocardial Infarction, Acute, Coronary Artery Disease
Evaluation of a Modified Anti-Platelet Therapy Associated With Low-dose DES Firehawk in Acute Myocardial Infarction Patients Treated With Complete Revascularization Strategy
The study aims to evaluate a modified antiplatelet therapy associated with Firehawk low-dose rapamycin DES in acute myocardial infarction patients treated with complete revascularization strategy.
- Trial name
- TARGET-FIRST (NCT04753749)
- Testing
- Shortened DAPT followed by P2Y12 inhibitor monotherapy (cessation of aspirin), Standard DAPT
- Where
- 40 sites in Austria, France and 4 more
- Volunteers
- 2,248 people
- Sponsor
- MicroPort CRM